Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical & Experimental Metastasis|September 1, 1995
Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domainT H Landowski, S Uthayakumar, J R StarkeyLeukemia|May 24, 2003
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanismsY Nefedova, T H Landowski, W S DaltonBiochemistry|September 5, 1995
Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature proteinT H Landowski, E A Dratz, J R StarkeyCurrent Opinion in Oncology|November 21, 2000
The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistanceK H Shain, T H Landowski, W S DaltonBlood|March 15, 1997
Selection for drug resistance results in resistance to Fas-mediated apoptosisT H Landowski, M C Gleason-Guzman, W S DaltonBlood|December 31, 1997
Mutations in the Fas antigen in patients with multiple myelomaT H Landowski, N Qu, I Buyuksal, et al.Blood|December 9, 1998
Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemiaT Lamy, J H Liu, T H Landowski, et al.Leukemia|May 10, 2000
Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell lineK H Shain, T H Landowski, I Buyuksal, et al.Blood|June 25, 1999
Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activationT H Landowski, K H Shain, M M Oshiro, et al.Leukemia & Lymphoma|November 8, 2001
CD95 antigen mutations in hematopoietic malignanciesT H Landowski, L Moscinski, R Burke, et al.Pageof 2